COMPANY
Allyx Therapeutics Inc.
Funding and NIH signals
- SEC Form D raise Raised $26.43M (Form D filed May 11, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001865257-26-000004 (May 11, 2026)
Evidence (2 events)
- May 11, 2026 · SEC Form D 0001865257-26-000004
Name of Issuer: Allyx Therapeutics, Inc.; CIK: 1865257; Address: New Haven, CT; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-05-04; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 29999999; Total Amount Sold: 26427730; Federal exemptions: 06b - Mar 3, 2026 · SEC Form D 0001865257-26-000003
Name of Issuer: Allyx Therapeutics, Inc.; CIK: 1865257; Address: New Haven, CT; Submission type: D; Filing date: 2026-03-03; Industry Group: Biotechnology; Date of First Sale: 2026-02-23; Types of Securities Offered: Option/warrant, Other (Simple Agreements for Future Equity (SAFEs)); Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 3324918; Federal exemptions: 06b
- May 11, 2026 · SEC Form D 0001865257-26-000004
Timeline
- Grant Government grant — SBIR: $1.67M (annual award, as published), announced Jun 27, 2025. Agency: NIH/NIA. Source: government award database. source ↗
- Trial start Phase 1: A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates source ↗
- Grant Government grant: $3.3M (total, as published), announced Oct 15, 2024. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 1: A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's source ↗
- Trial start Phase 1: A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease source ↗
- Trial start Phase 1: Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers source ↗
Funding
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05804383 | A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease | Phase 1 | Completed | Mar 28, 2023 | Jul 15, 2025 (actual) |
| NCT06632990 | A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates | Phase 1 | Active, not recruiting | Nov 4, 2024 | Apr 3, 2025 (estimated) |
| NCT05817643 | Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers | Phase 1 | Unknown status (ClinicalTrials.gov) | Jan 10, 2023 | Feb 27, 2023 (actual) |
| NCT06309147 | A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's | Phase 1 | Unknown status (ClinicalTrials.gov) | Mar 15, 2024 | Feb 15, 2025 (estimated) |
NIH awards 3
- NIH award 1SB1AG087748-01 FY2024: $1,678,603 awarded for that fiscal year; activity SB1 (SBIR); PI SIEGERT, TIMOTHY R; recipient as written: ALLYX THERAPEUTICS INC., New Haven, CT. Clinical evaluation of BMS-984923 m source ↗
- NIH award 5R44AG077984-02 FY2023: $1,339,527 awarded for that fiscal year; activity R44 (SBIR); PI SIEGERT, TIMOTHY R; recipient as written: ALLYX THERAPEUTICS INC., New Haven, CT. BMS-984923 Non-Clinical Development source ↗
- NIH award 1R44AG077984-01A1 FY2022: $680,220 awarded for that fiscal year; activity R44 (SBIR); PI SIEGERT, TIMOTHY R; recipient as written: ALLYX THERAPEUTICS INC., New Haven, CT. BMS-984923 Non-Clinical Development source ↗